<SEC-DOCUMENT>0001193125-13-431411.txt : 20131107
<SEC-HEADER>0001193125-13-431411.hdr.sgml : 20131107
<ACCEPTANCE-DATETIME>20131107070700
ACCESSION NUMBER:		0001193125-13-431411
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20131107
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20131107
DATE AS OF CHANGE:		20131107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OMEROS CORP
		CENTRAL INDEX KEY:			0001285819
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911663741
		STATE OF INCORPORATION:			WA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34475
		FILM NUMBER:		131198412

	BUSINESS ADDRESS:	
		STREET 1:		201 ELLIOT AVENUE WEST
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98119
		BUSINESS PHONE:		206-676-5000

	MAIL ADDRESS:	
		STREET 1:		201 ELLIOT AVENUE WEST
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98119
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d624096d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, DC 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section 13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): November 7, 2013 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>OMEROS CORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Washington</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-34475</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>91-1663741</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>201 Elliott Avenue West </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seattle, Washington 98119 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices, including zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(206) 676-500</B>0 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or former address, if changed since last report) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form&nbsp;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;2.02 Results of Operation and Financial Condition. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November 7, 2013, Omeros Corporation issued a press release announcing financial results for the three and nine months ended
September&nbsp;30, 2013. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
information in this Current Report on Form 8-K, including the exhibit hereto, shall not be deemed to be &#147;filed&#148; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that
Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the United States Securities and Exchange
Commission made by Omeros Corporation, whether made before or after the date hereof, regardless of any general incorporation language in such filing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01 Financial Statements and Exhibits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Exhibits. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press release dated November 7, 2013 relating to Omeros&#146; financial results for the three and nine months ended September 30, 2013.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="91%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>OMEROS CORPORATION</B></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Gregory A. Demopulos</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Gregory A. Demopulos, M.D.</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">President, Chief Executive Officer, and</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chairman of the Board of Directors</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: November 7, 2013 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press release dated November 7, 2013 relating to Omeros&#146; financial results for the three and nine months ended September 30, 2013.</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d624096dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g624096g96d56.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Omeros Corporation Reports Third Quarter 2013 Financial Results </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&#151; Obtains Additional $17.4 Million in Cash in 4Q 2013 &#151; </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SEATTLE, WA&#150;November 7, 2013</B>&#150; <B> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Received $17.4 million in cash in October 2013 </I></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Total operating expenses in 3Q 2013 were $13.6 million including $3.2 million in non-cash expenses compared to $13.3 million including non-cash expenses of $2.1 million in 2Q 2013 </I></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>U.S. and European regulators accepted Omeros&#146; OMS302 marketing applications for review </I></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>OMS824 and OMS721 Phase 1 clinical programs generated positive data </I></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Increased the number of unlocked orphan GPCRs to 52 </I></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Omeros Corporation (NASDAQ: OMER), a
clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its financial results for the third
quarter of 2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Throughout the third quarter of 2013, we continued to make significant strides in development across our pipeline,&#148; stated
Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. &#147;For OMS302, the marketing applications were accepted for review by both the FDA and EMA, and the market launch is planned for the second half of 2014. Our OMS824
program for the treatment of cognitive disorders was granted orphan drug designation by the FDA, generated positive Phase 1 clinical trial results, began enrollment in a Phase 2 trial in patients with schizophrenia and is now initiating a Phase 2
trial in Huntington&#146;s disease. OMS721, our MASP-2 inhibitor, entered a Phase 1 clinical trial from which we reported positive data today, and a Phase 2 trial to evaluate the molecule&#146;s efficacy and safety in patients with thrombotic
microangiopathies is planned for early 2014. Preclinically, our GPCR platform continued to identify functionally active compounds against an unprecedented number of orphan receptors, and our addiction and high-risk bleeding programs advanced toward
the clinic. Following the close of the quarter, we added over $17 million to our balance sheet, positioning Omeros to execute on a series of value-driving milestones during the remainder of 2013 and well into 2014.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Third Quarter and Recent Highlights </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Reported U.S. and European regulators had accepted Omeros&#146; OMS302 marketing applications for review. OMS302, added to standard irrigation solution used during ophthalmological procedures, is Omeros&#146;
proprietary PharmacoSurgery<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> product designed to maintain intraoperative mydriasis, prevent miosis and reduce postoperative pain and irritation resulting from cataract and other lens
replacement surgery. Omeros is preparing for a planned commercial launch of OMS302 in the second half of 2014. </TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Announced that Omeros entered into a settlement agreement with Carolina Casualty Insurance Company, or, CCIC, dated October&nbsp;2, 2013, related to CCIC&#146;s defense of, and coverage obligations owed to, Omeros and
its chief executive officer and chairman, Dr.&nbsp;Demopulos, in previously settled litigation with Omeros&#146; former chief financial officer. The settlement included a release of each party&#146;s respective claims in the insurance coverage
lawsuit and payment by CCIC of $12.5 million to Omeros, which was received on October&nbsp;24, 2013. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Reported positive clinical data from its Phase 1 clinical program evaluating OMS824, the lead compound from its phosphodiesterase 10 (PDE10) program. OMS824 selectively inhibits PDE10, an enzyme expressed in areas of
the brain linked to a wide range of diseases that affect cognition, including Huntington&#146;s disease and schizophrenia. Omeros subsequently started a Phase 2 trial evaluating the drug in patients with schizophrenia and plans to start a Phase 2
trial in Huntington&#146;s disease in early 2014. OMS824 has received orphan drug designation from the FDA for the treatment of Huntington&#146;s disease. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Reported positive clinical data from its Phase 1 clinical trial of OMS721, the company&#146;s lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), an important regulator
of the lectin pathway of the immune system. A Phase 2 clinical program to evaluate OMS721 in the treatment of thrombotic microangiopathies (TMAs), a family of disorders that occurs in the microcirculation of the body&#146;s organs, most commonly the
kidney and brain, is expected to begin enrollment in early 2014. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Announced that its proprietary Cellular Redistribution Assay technology had &#147;unlocked&#148; six additional Class&nbsp;A orphan G protein-coupled receptors (GPCRs) for drug development, bringing the total number of
Class&nbsp;A orphan GPCRs &#147;unlocked&#148; by Omeros to 52. These six orphan GPCRs are linked to a series of important indications, including cardiovascular indications, certain types of cancer and Grave&#146;s disease. Omeros also announced
that it had identified small molecules that interact with two non-orphan Class B GPCRs, the glucagon-like peptide 1 receptor (GLP-1R) and the parathyroid hormone 1 receptor (PTH-1R). Both of these receptors are established drug targets &#150; GLP-1R
for diabetes and PTH-1R for osteoporosis. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Results </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total operating expenses for the quarter ended September&nbsp;30, 2013 were $13.6 million and included non-cash expenses of $3.2 million related to rent
expense and stock-based compensation. For the same period in 2012, total operating expenses were $14.5 million, which included non-cash rent and stock-based compensation expenses of $576,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The decrease in total operating expenses for the quarter ended September&nbsp;30, 2013 compared to the prior year quarter is primarily due to a litigation
settlement expense of $3.95 million recorded in the same period in 2012, which was reimbursed by CCIC in the fourth quarter of 2012. For the quarter ended September&nbsp;30, 2013, total (i.e., cash and non-cash) operating expenses, excluding the
litigation expense, increased by $3.1 million compared to the same period in 2012. The increase was primarily due to the non-cash rent and stock-based compensation expenses of $3.2 million in 3Q 2013 compared to $576,000 in 3Q 2012. The remaining
increases were related to conducting the company&#146;s Phase 1 clinical program evaluating OMS824, advancing our MASP-2 program, preparing the New Drug Application (NDA) and Marketing Authorization Application (MAA) for OMS302, planning for the
commercial launch of </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
OMS302 in the second half of 2014, and non-recurring legal expenses incurred in connection with the CCIC matter. These higher costs were partially offset by lower overall clinical trial expenses
related to the completion of the company&#146;s OMS302 Phase 3 clinical program in January 2013 and the completion of the company&#146;s first OMS103HP Phase 3 clinical trial in arthroscopic partial meniscectomy patients in December 2012. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total revenue for the quarter ended September&nbsp;30, 2013 was $196,000 compared to $1.4 million for the same period in 2012. This decrease was primarily due
to lower revenue recognized from the company&#146;s GPCR platform development funding agreement with Vulcan Inc. and its affiliate. While research continues under the company&#146;s GPCR program, no additional deferred revenue under the Vulcan
agreement remains to be recognized after the first quarter of 2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the quarter ended September&nbsp;30, 2013, Omeros reported a net loss of $13.9
million, or $0.46 per share, inclusive of the above-referenced $3.2 million of non-cash charges equaling $0.11 per share, compared to a net loss of $13.3 million, or $0.51 per share, inclusive of the above-referenced $576,000 of non-cash charges
equaling $0.02 per share, for the same period in 2012. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At September&nbsp;30, 2013, Omeros had cash, cash equivalents and short-term investments of $9.0
million. On October&nbsp;24, 2013, subsequent to the end of the quarter, Omeros received a payment of $12.5 million from CCIC pursuant to the terms of the settlement agreement. Omeros also received $4.9 million in net proceeds from the sale of
373,700 shares of its common stock, sold at an average price of $13.29 per share, pursuant to the company&#146;s at-the-market equity facility in October 2013. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Omeros Corporation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Omeros is a clinical-stage
biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics targeting inflammation, coagulopathies and disorders of the central nervous system. Derived from its proprietary
PharmacoSurgery<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> platform, the Company&#146;s lead drug product, OMS302 for lens replacement surgery, is currently under review for marketing approval by both the US Food and Drug
Administration and the European Medicines Agency with commercial launch planned for the second half of 2014. Omeros&#146; five other clinical programs are focused on schizophrenia, Huntington&#146;s disease and cognitive impairment; addictive and
compulsive disorders; complement-related diseases; and preventing problems associated with surgical procedures. Omeros also has a proprietary GPCR platform, which is making available an unprecedented number of new GPCR drug targets and corresponding
compounds to the pharmaceutical industry for drug development. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act of 1933 and Section&nbsp;21E of the
Securities Exchange Act of 1934, which are subject to the &#147;safe harbor&#148; created by those sections for such statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by
terms such as &#147;anticipate,&#148; &#147;believe,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;goal,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148;
&#147;project,&#148; &#147;should,&#148; &#147;will,&#148; &#147;would&#148; and similar expressions. Forward-looking statements are based on management&#146;s beliefs and assumptions and on information available to management only as of the date of
this press release. Omeros&#146; actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with Omeros&#146; unproven preclinical and clinical
development activities, regulatory oversight, commercialization of its products, intellectual property claims and the risks, uncertainties and other factors described under the heading &#147;Risk Factors&#148; in the Company&#146;s Quarterly Report
on Form 10-Q filed with the Securities and Exchange Commission on August&nbsp;9, 2013. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation
to update these forward-looking statements, even if new information becomes available in the future. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact: </B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jennifer Cook Williams </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cook Williams Communications, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investor and Media Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">360.668.3701 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">jennifer@cwcomm.org </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OMEROS CORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF OPERATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended<BR>September 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended </B><br><B>September 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Litigation settlement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,953</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,953</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,453</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,434</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,036</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36,614</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,352</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investment income</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(592</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(413</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,768</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,360</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, (expense) net</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,870</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,276</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(37,951</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(30,710</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per common share</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.46</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.51</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.36</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used to compute</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">basic and diluted net loss per common share</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,844,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,834,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,984,133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,578,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OMEROS CORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED BALANCE SHEET DATA </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,<BR>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents and short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total notes payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(252,528</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(214,577</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,893</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,531</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g624096g96d56.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g624096g96d56.jpg
M_]C_X``02D9)1@`!`@$!+`$L``#_X1!Z17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````4````<@$R``(````4````AH=I``0````!````G````,@```$L````
M`0```2P````!061O8F4@4&AO=&]S:&]P(#<N,``R,#$S.C$Q.C`V(#(P.C,Q
M.C4W``````.@`0`#`````0`!``"@`@`$`````0```+"@`P`$`````0```'8`
M````````!@$#``,````!``8```$:``4````!```!%@$;``4````!```!'@$H
M``,````!``(```(!``0````!```!)@("``0````!```/3`````````!(````
M`0```$@````!_]C_X``02D9)1@`!`@$`2`!(``#_[0`,061O8F5?0TT``?_N
M``Y!9&]B90!D@`````'_VP"$``P("`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43
M$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-
M$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#/_``!$(`%8`@`,!(@`"$0$#$0'_W0`$``C_Q`$_```!
M!0$!`0$!`0`````````#``$"!`4&!P@)"@L!``$%`0$!`0$!``````````$`
M`@,$!08'"`D*"Q```00!`P($`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R
M!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5
MXF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7
MI[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q
M0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*S
MA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_
MV@`,`P$``A$#$0`_`/54DDDE*22224I))5\_+9A8=V4_BII('B>&-_MO]J$I
M"(,CH`+*0#(@#4DT'%ZGUQU'7L>ECB,?'(9D#LXVQ_YX_1O71+@,=EI9D=1N
M:;35[BXZCU[CMK<_^35O];_ME=3T'J==W2:W9%H:^@^C8]Y`DM^@XN=^_5M<
MJ')\R9SF)FO<O)`'I"/H;W-\N(P@8"_;K'.NLCZW620Z;Z;ZQ;0]ME;IVO:9
M!@[3!"(M`$$6&@00:*DDDDE*22224I))))3_`/_0]522224I))))2ES/UMS-
M[ZNGUF=H]:Z/'Z-##_:]_P#VVNE)#07.,`:DG@!<OTQ@ZKUJS-<R:B1;J.&,
M.S$:[^79L];^PJG.DRC'#'YLIX?\`?,VN3`$I99?+B%_X9^5-EG'Z1T)N!:T
M69&4UWJ-YU=].QW_`!?T*USN+C?:LFK&W-8ZT[6O?Q,:?YRU>MU6YG6K*9,[
MF4U@F``X,]W^?:]Z;ZR=,&#=1=C2RI[0P$<MLKU8_=^]8W_SVL_F(&9E(1_4
M\L1BX>IB#PG5OX)"(C$R_6\P#DOIQ4Z.-U?!Z*?V1>+2,<P<C:"T^I^GW;6'
M?[?5_<6[5;7=6VVIP?6\2US3((6.WIO3.NXC<\L-63>T;[:R00]OL<US?H/V
M.;L][4'ZMC)PLW,Z3>9%46L(X]VFYO\`)M]C_P"OO5_%DR0G"!$3@R:891_1
MC7%CA/\`P&CEQXYPG($C-CUS1E^E+Y9SC_AO0I))*XU%))))*4DDDDI__]'U
M5))))2DDDDE.;URRUV,W!HTNSG>BTG@-@NN<='?X,(W2^GU]/Q&T-U>?=:[]
MY\`$_P!7V[&?R$;[.TY7VEQEP9Z=8_=!.ZS^U9[/^VU.X7&IPH+6VQ["\%S9
M_E-:YCO^DHAC_62RR%RKA@.T/^^DRF?HCC!J-\4_&7_H+C=4PQ5U"K-U+'V5
MN<)X=7I/]JO\S_@UKY&-C95?IY%;;JY#@UP!$CARY?-^L/6,>Q^)G8^,UT:L
M<UQ:X=GL_2>]B?I/UAS7YN/B15Z-KPTM]Q+1!/Z-SGGP_.52'-8(Y90H_K):
MQE':?BVI<MG..,K'ZL6)1E^AX/1AO3^F8[B!7BXX=+CHUNYT-_Z2SL7J72AF
MY.=;ETAUP974W<)%=>Z-W\NRQ]C_`/B_25SK.#=G]/LQJ7-;8XL(+YCVN:\_
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M7[R6_I*VN]S/S_\`C$!"1XJ'RZE)G$<-GYM`]:DJ?6.HU]+Z7E=0L@MQJW/#
M28W.`_1US_PEFVM97U+^L.;U_I]^3FUU564W>D&T[HC979)]1SOSK$A`F)ET
M!I1F!(1ZD6[EV-C9&WUZF6[9V[VAT3SMW*#,#`K>'LQJF/:9:YK&@@^1`6)]
M9_K8[I.11TOIU`S>KY9:*J7':Q@>=E;[G?RW_1K_`.,LLLJ1L,?72B^EV<[!
MS,>QX&0RAME3ZFG_``E-EKK&7MK_`''LK>]`X1I(B.NU_,:2,QUB#+3>MG=2
M7/?77ZQ9GU>Z=1EXE==KK+O2>VW=&W999[=A;[OT:S>I?6KZS]#KQ<[J>'B9
M/3LG:"_$=8VQI<WU`S;?N;OV[MGYEG_`IT<4I`$5KMKV6RRQB2#>F_@]FDA8
MN33EXU650[=3>QME;N):\;V&#_)*YK(^M74>H]:LZ)]6J:K+,:?MF=D[O1KV
MG8]M=5>U]S_4_1_2_G/^"_2H1@3?AO?1)D!7CMXO5)+E,SZU]1Z'UQN#UVFK
M]G9CW'"SJ-PVLW;0W*987>ZK?5Z[Z_H?SO\`4Z?(OIQJ+,B]PKII:;+'G@-:
M-SW?YJ1@17];:E"0-_U=TB2Y3I/7?K%]9+CE=+JIZ?T>JP-];):ZR^[:?TC&
M4L?774W\U_O_`$?_`&XM;K&7U*BZAN(W]&XRXAA?N,_S6GT/^_\`^DK])$P(
M/"2+_)'&*XM:?__3N?4^P]3^O^=GVG<YK<BQA.L`/KQ*6_V,?V+M/K5CLR?J
MWU.IXD?9K'B?WJVFZL_V7UM7%?45GV/Z[]1Q+-'AF34T>)9?6\?YU?O7:?6S
M(9C?5KJ=KS`.-8P'^58/1K']I]BL9?YV%=HTU\/\U.^\[>?_`,5F6^WI.7BN
M,MQ[]S/(6M#RW_MQMCUR_6FVX/6,KK].KL7K%E;F]I8VO*K'_7F_:*UU'^*S
M$?7TK,RG"&Y%X97YBIH8YW_;CGL_L*I;T[]H]*^M]0;NMJZ@^^GQWU,KM]O]
M=K7U?VT_B`RS[6`?\+YEG"988=P"1_@[.E]=LEG4L;I?2L:S]%U5YR'O:><?
M'K.8YW]IWHN0?\51W=#RSXY9/_@5"I_5&O\`:/37]5LL#ST[IUG3&5GEI!?D
M>J!_PN(_$JW_`/!6JW_BH_Y!R?\`PT?_`#U0FR'#BE#]TC[5T3Q983_>B?L<
MOHMS,O\`QD9V=E/:QF*[((>X@-`JV]/JW.=_(<O06=2Z=98VJO*I?8_1C&V-
M+B>?:T.W.7G/1</&'^,#J/3.HTLNIRG9333:T/8X.>S/IW,=[?YMGJ+O,;ZL
M_5[$R*\G%Z;C47U&:[:ZFM<TD;?:Y@_=<FY^&XW?RCAI=@NI57SRNWG?\:W_
M`(G\?_PT/_/60H?7O+J_YL8'3:_TN;ENQ_0QV#=80T;MS:V^[Z>VK_KBG_C7
M_P#$_C_^&A_YZR%F?6.NSH'6>D?6JEI=5=757EQJ2YM?IOY_.NPMWI?\)C)V
M(7''W!D8^,AT6Y3ZLG8B(EX1>GVY'U?^HY:3&5@X)UT]MNS^3^Y:Y8W^*C'#
M.GY]_=]S*I\JV!__`*/<ND^L=8ZA]6,]N.?4%V*]]1;KN]OJ,V_UUSW^*J]K
M^D9M(Y9D^I\K*ZMO_GI-!O#D/4R%KB*S8QT$323_`!I8S+.AXUQ:"ZK):W=X
M-L98Q[?[3O31\9N7UO\`Q<"NN795N&:V@<O=3->W^M=Z.U5_\:>0ROHF+070
M^W*#]OBVMECGG^RYU:V_J=B68?U8Z=1:(?Z(L</#U2Z_;_X(E=88'J)V$`7G
MF.A@`7G_`/%K]8<2S!;T.UPKR:7/?C`Z>K6]SK[&M_X:A[K/4K_T7O\`]+Z?
M<KSW_&)]6Z<0-^L/3R<:XW-^TBL[?TCC^BS:H_F\CU=GJ[/YW^=_G/4]7LOJ
M_GV]1Z)@YUPBW(I8^SM+B/>X#]U[O<AE`(&2.TCJ.TEV$R!..6\!H?WH/__4
MV?K#C8[OK?1E=`RZV_6*HCUL&UMGIV@5EVM[*W5UO=B?H[=S_P";]+^9N_G9
M_6I_7>I8+*^KU5]!Z.VQAR[A8[+L<9_0L97BU;6L]3_3?X7TO^*L\.25D?Y/
MO0KB_G/\#]'^Y[C6/^4\S?#_`#?^'^E_?X'Z;Z$.F-Z1B-Z2X.P!6!CN;W;W
M<Z0UWJ[_`.>W^_U?YQ97U2K:S,^L)]1EF[J5I<&[O;[6>RSU&5MW?\7ZC%\\
MI*+IDW^N_P`W5EZPVV.S]`_5JGI-7U3S:^D7MR*=V43:0]HW.W.J:\6,;9^B
MQCCU_P`VJO\`BNJ;5T7*:VZN\')G=5OC^:I]OZ>JAW_17A"2?+Y<F_S#=9'Y
M\>WRG;]C[?\`6W%P+?K+BW=)S68_UEJ=7&,YECF6_2=5ZMM%=C:K/2W,?ZCO
MZ+_.^G7Z=BZ#%SOK9D74UW=,Q\&H.!R;GY'K2P?3;C4TL8[U'_F/N?\`H_\`
MA%\X))2^2%UMIQ[_`.#P_H_WU1^>==]>#_N^+]+^X^\?XT:FV]$QFNNKH`R9
MW6[X_FKO;^@JO=_T5;^M-6!9]2S7G7,H!JI]"YP<X"X!IHVAK'6_I'>Q^VO^
M9]1?/B24?EQ;_,=E2KBR;?*-WZ+^HXSV?5S&KS"Q[6#]4M87G?01NHW"]E-C
M=D^DW]'_`#3*USG1*W8?7<W*^IUE75,"R/M>`\OH-9+G^E]GR;*OLUC6/%OV
M?_@/T?[F0O%TD1OE_'_-[_I?^@*.V+\/W]OT?_0WVGK=7VSK>%E_7*VKI>"R
M?L?3V;[R\AU?K?:<EE7V=C'O]'U_^`_T?Z2Y>@KY523,NT/(U7R?X/\`W7$N
MQ;S\Q_?_`,)]R^MS<_J#6#KSF]%^K]-X#G,+LC(O<-_INC&KLKQJGL_F_4^A
M9_PGIUKL<'[+]BQ_L4?9/29]GV_1]/:/2VS^;Z:^7$DI_)'MKM\G_?<2H?/+
MR&_S_P#>\+__V?_M%0I0:&]T;W-H;W`@,RXP`#A"24T$)0``````$```````
M```````````````X0DE-`^T``````!`!+`````$``0$L`````0`!.$))300F
M```````.`````````````#^````X0DE-!`T```````0````>.$))3009````
M```$````'CA"24T#\P``````"0```````````0`X0DE-!`H```````$``#A"
M24TG$```````"@`!``````````$X0DE-`_4``````$@`+V9F``$`;&9F``8`
M``````$`+V9F``$`H9F:``8```````$`,@````$`6@````8```````$`-0``
M``$`+0````8```````$X0DE-`_@``````'```/______________________
M______\#Z`````#_____________________________`^@`````________
M_____________________P/H`````/____________________________\#
MZ```.$))300(```````0`````0```D````)``````#A"24T$'@``````!```
M```X0DE-!!H``````TL````&``````````````!V````L`````L`-@`R`#0`
M,``Y`#8`7P`P`#``,0`U`````0`````````````````````````!````````
M``````"P````=@`````````````````````!````````````````````````
M`!`````!````````;G5L;`````(````&8F]U;F1S3V)J8P````$```````!2
M8W0Q````!`````!4;W`@;&]N9P``````````3&5F=&QO;F<``````````$)T
M;VUL;VYG````=@````!29VAT;&]N9P```+`````&<VQI8V5S5FQ,<P````%/
M8FIC`````0``````!7-L:6-E````$@````=S;&EC94E$;&]N9P`````````'
M9W)O=7!)1&QO;F<`````````!F]R:6=I;F5N=6T````,15-L:6-E3W)I9VEN
M````#6%U=&]'96YE<F%T960`````5'EP965N=6T````*15-L:6-E5'EP90``
M``!);6<@````!F)O=6YD<T]B:F,````!````````4F-T,0````0`````5&]P
M(&QO;F<``````````$QE9G1L;VYG``````````!"=&]M;&]N9P```'8`````
M4F=H=&QO;F<```"P`````W5R;%1%6%0````!````````;G5L;%1%6%0````!
M````````37-G951%6%0````!```````&86QT5&%G5$585`````$```````YC
M96QL5&5X=$ES2%1-3&)O;VP!````"&-E;&Q497AT5$585`````$```````EH
M;W)Z06QI9VYE;G5M````#T53;&EC94AO<GI!;&EG;@````=D969A=6QT````
M"79E<G1!;&EG;F5N=6T````/15-L:6-E5F5R=$%L:6=N````!V1E9F%U;'0`
M```+8F=#;VQO<E1Y<&5E;G5M````$453;&EC94)'0V]L;W)4>7!E`````$YO
M;F4````)=&]P3W5T<V5T;&]N9P`````````*;&5F=$]U='-E=&QO;F<`````
M````#&)O='1O;4]U='-E=&QO;F<`````````"W)I9VAT3W5T<V5T;&]N9P``
M````.$))3004```````$`````CA"24T$#``````/:`````$```"`````5@``
M`8```($````/3``8``'_V/_@`!!*1DE&``$"`0!(`$@``/_M``Q!9&]B95]#
M30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\,#`\5
M&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`$-
M"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`5@"``P$B``(1`0,1`?_=``0`"/_$
M`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!`0$!`0$`````
M`````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$%05%A
M$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C
M=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='
M5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B$P4R
M@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D154V
M=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'
MEZ>WQ__:``P#`0`"$0,1`#\`]522224I))))2DDE7S\MF%AW93^*FD@>)X8W
M^V_VH2D(@R.@`LI`,B`-230<7J?7'4=>QZ6.(Q\<AF0.SC;'_GC]&]=$N`QV
M6EF1U&YIM-7N+CJ/7N.VMS_Y-6_UO^V5U/0>IUW=)K=D6AKZ#Z-CWD"2WZ#B
MYW[]6URH<GS)G.8F:]R\D`>D(^AO<WRXC"!@+]NL<ZZR/K=9)#IOIOK%M#VV
M5NG:]ID&#M,$(BT`018:!!!HJ22224I))))2DDDDE/\`_]#U5))))2DDDDE*
M7,_6W,WOJZ?69VCUKH\?HT,/]KW_`/;:Z4D-!<XP!J2>`%R_3&#JO6K,US)J
M)%NHX8P[,1KOY=FSUO["J<Z3*,<,?FRGA_P!\S:Y,`2EEE\N(7_AGY4V6<?I
M'0FX%K19D937>HWG5WT['?\`%_0K7.XN-]JR:L;<UCK3M:]_$QI_G+5ZW5;F
M=:LIDSN936"8`#@SW?Y]KWIOK)TP8-U%V-+*GM#`1RVRO5C]W[UC?_/:S^8@
M9F4A']3RQ&+AZF(/"=6_@D(B,3+];S`.2^G%3HXW5\'HI_9%XM(QS!R-H+3Z
MGZ?=M8=_M]7]Q;M5M=U;;:G!];Q+7-,@A8[>F],Z[B-SRPU9-[1OMK)!#V^Q
MS7-^@_8YNSWM0?JV,G"S<SI-YD51:PCCW:;F_P`FWV/_`*^]7\63)"<($1.#
M)IAE']&-<6.$_P#`:.7'CG"<@2,V/7-&7Z4OEG./^&]"DDDKC44DDDDI2222
M2G__T?54DDDE*22224YO7++78S<&C2[.=Z+2>`V"ZYQT=_@PC=+Z?7T_$;0W
M5Y]UKOWGP`3_`%?;L9_(1OL[3E?:7&7!GIUC]T$[K/[5GL_[;4[A<:G"@M;;
M'L+P7-G^4UKF._Z2B&/]9++(7*N&`[0_[Z3*9^B.,&HWQ3\9?^@N-U3#%74*
MLW4L?96YPGAU>D_VJ_S/^#6OD8V-E5^GD5MNKD.#7`$2.'+E\WZP]8Q['XF=
MCXS71JQS7%KAV>S])[V)^D_6'-?FX^)%7HVO#2WW$M$$_HW.>?#\Y5(<U@CE
ME"C^LEK&4=I^+:ERV<XXRL?JQ8E&7Z'@]&&]/Z9CN(%>+CATN.C6[G0W_I+.
MQ>I=*&;DYUN72'7!E=3=PD5U[HW?R[+'V/\`^+])7.LX-V?T^S&I<UMCBP@O
MF/:YKS]$._=6)C_5++;:#>^FRO4.'OF(Y'T?=_:4F>6>.2$<6(2A'6]HB1]+
M'A&&6.<LN0QG+0C]*4?3)Z#&ZC@Y;BW&O9<6_2V&8G]Z%90,;$HQ:Q72W:UO
M`DQ_TB4=6H<7"..N+^KLUI\-^B^'^MNI))).6J22224__]+U5)<[]8_K6[IN
M71TCIE`S>L99'ITD[:V!T[;+W_V7.]/_`$?Z6ST_\)5ZQUSZT_5ZK&SNH48V
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M#Y$!8GUG^MCNDY%'2^G4#-ZOEEHJI<=K&!YV5ON=_+?]&O\`XRRRRI&PQ]=*
M+Z79SL',Q['@9#*&V5/J:?\`"4V6NL9>VO\`<>RM[T#A&DB(Z[7\QI(S'6(,
MM-ZV=U)<]]=?K%F?5[IU&7B5UVNLN])[;=T;=EEGMV%ON_1K-ZE]:OK/T.O%
MSNIX>)D].R=H+\1UC;&ES?4#-M^YN_;NV?F6?\"G1Q2D`16NVO9;++&)(-Z;
M^#V:2%BY-.7C595#MU-[&V5NXEKQO88/\DKFLCZU=1ZCUJSHGU:IJLLQI^V9
MV3N]&O:=CVUU5[7W/]3]']+^<_X+]*A&!-^&]]$F0%>.WB]4DN4S/K7U'H?7
M&X/7::OV=F/<<+.HW#:S=M#<IEA=[JM]7KOK^A_._P!3I\B^G&HLR+W"NFEI
MLL>>`UHW/=_FI&!%?UMJ4)`W_5W2)+E.D]=^L7UDN.5TNJGI_1ZK`WULEKK+
M[MI_2,92Q]==3?S7^_\`1_\`;BUNL9?4J+J&XC?T;C+B&%^XS_-:?0_[_P#Z
M2OTD3`@\)(O\D<8KBUI__].Y]3[#U/Z_YV?:=SFMR+&$ZP`^O$I;_8Q_8NT^
MM6.S)^K?4ZGB1]FL>)_>K:;JS_9?6U<5]16?8_KOU'$LT>&9-31XEE];Q_G5
M^]=I];,AF-]6NIVO,`XUC`?Y5@]&L?VGV*QE_G85VC37P_S4[[SMY_\`Q69;
M[>DY>*XRW'OW,\A:T/+?^W&V/7+]:;;@]8RNOTZNQ>L65N;VEC:\JL?]>;]H
MK74?XK,1]?2LS*<(;D7AE?F*FACG?]N.>S^PJEO3OVCTKZWU!NZVKJ#[Z?'?
M4RNWV_UVM?5_;3^(#+/M8!_POF6<)EAAW`)'^#LZ7UVR6=2QNE]*QK/T757G
M(>]IYQ\>LYCG?VG>BY!_Q5'=T/+/CED_^!4*G]4:_P!H]-?U6RP//3NG6=,9
M6>6D%^1ZH'_"XC\2K?\`\%:K?^*C_D')_P##1_\`/5";(<.*4/W2/M71/%EA
M/]Z)^QR^BW,R_P#&1G9V4]K&8KL@A[B`T"K;T^K<YW\AR]!9U+IUEC:J\JE]
MC]&,;8TN)Y]K0[<Y><]%P\8?XP.H],ZC2RZG*=E---K0]C@Y[,^G<QWM_FV>
MHN\QOJS]7L3(KR<7IN-1?49KMKJ:US21M]KF#]UR;GX;C=_*.&EV"ZE5?/*[
M>=_QK?\`B?Q__#0_\]9"A]>\NK_FQ@=-K_2YN6[']#'8-UA#1NW-K;[OI[:O
M^N*?^-?_`,3^/_X:'_GK(69]8Z[.@=9Z1]:J6EU5U=5>7&I+FU^F_G\Z["W>
ME_PF,G8A<<?<&1CXR'1;E/JR=B(B7A%Z?;D?5_ZCEI,96#@G73VV[/Y/[EKE
MC?XJ,<,Z?GW]WW,JGRK8'_\`H]RZ3ZQUCJ'U8SVXY]078KWU%NN[V^HS;_77
M/?XJKVOZ1FTCEF3ZGRLKJV_^>DT&\.0]3(6N(K-C'01-)/\`&EC,LZ'C7%H+
MJLEK=W@VQEC'M_M.]-'QFY?6_P#%P*ZY=E6X9K:!R]U,U[?ZUWH[57_QIY#*
M^B8M!=#[<H/V^+:V6.>?[+G5K;^IV)9A_5CIU%HA_HBQP\/5+K]O_@B5UA@>
MHG80!>>8Z&`!>?\`\6OUAQ+,%O0[7"O)I<]^,#IZM;W.OL:W_AJ'NL]2O_1>
M_P#TOI]RO/?\8GU;IQ`WZP]/)QKC<W[2*SM_2./Z+-JC^;R/5V>KL_G?YW^<
M]3U>R^K^?;U'HF#G7"+<BEC[.TN(][@/W7N]R&4`@9([2.H[2783($XY;P&A
M_>@__]39^L.-CN^M]&5T#+K;]8JB/6P;6V>G:!67:WLK=76]V)^CMW/_`)OT
MOYF[^=G]:G]=ZE@LKZO57T'H[;&'+N%CLNQQG]"QE>+5M:SU/]-_A?2_XJSP
MY)61_D^]"N+^<_P/T?[GN-8_Y3S-\/\`-_X?Z7]_@?IOH0Z8WI&(WI+@[`%8
M&.YO=O=SI#7>KO\`Y[?[_5_G%E?5*MK,SZPGU&6;NI6EP;N]OM9[+/496W=_
MQ?J,7SRDHNF3?Z[_`#=67K#;8[/T#]6J>DU?5/-KZ1>W(IW91-I#VC<[<ZIK
MQ8QMGZ+&./7_`#:J_P"*ZIM71<IK;J[P<F=U6^/YJGV_IZJ'?]%>$))\OER;
M_,-UD?GQ[?*=OV/M_P!;<7`M^LN+=TG-9C_66IU<8SF6.9;])U7JVT5V-JL]
M+<Q_J._HO\[Z=?IV+H,7.^MF1=37=TS'P:@X')N?D>M+!]-N-32QCO4?^8^Y
M_P"C_P"$7S@DE+Y(76VG'O\`X/#^C_?5'YYUWUX/^[XOTO[C[Q_C1J;;T3&:
MZZN@#)G=;OC^:N]OZ"J]W_15OZTU8%GU+->=<R@&JGT+G!S@+@&FC:&L=;^D
M=['[:_YGU%\^))1^7%O\QV5*N+)M\HW?HOZCC/9]7,:O,+'M8/U2UA>=]!&Z
MC<+V4V-V3Z3?T?\`-,K7.=$K=A]=S<KZG65=4P+(^UX#R^@UDN?Z7V?)LJ^S
M6-8\6_9_^`_1_N9"\721&^7\?\WO^E_Z`H[8OP_?V_1_]#?:>MU?;.MX67]<
MK:NEX+)^Q]/9OO+R'5^M]IR65?9V,>_T?7_X#_1_I+EZ"OE5),R[0\C5?)_@
M_P#=<2[%O/S']_\`PGW+ZW-S^H-8.O.;T7ZOTW@.<PNR,B]PW^FZ,:NRO&J>
MS^;]3Z%G_">G6NQP?LOV+'^Q1]D])GV?;]'T]H]+;/YOIKY<22G\D>VNWR?]
M]Q*A\\O(;_/_`-[PO__9.$))300A``````!5`````0$````/`$$`9`!O`&(`
M90`@`%``:`!O`'0`;P!S`&@`;P!P````$P!!`&0`;P!B`&4`(`!0`&@`;P!T
M`&\`<P!H`&\`<``@`#<`+@`P`````0`X0DE-!`8```````<`"``!``$!`/_A
M$DAH='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O`#P_>'!A8VME="!B96=I
M;CTG[[N_)R!I9#TG5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED)S\^"CP_861O
M8F4M>&%P+69I;'1E<G,@97-C/2)#4B(_/@H\>#IX87!M971A('AM;&YS.G@]
M)V%D;V)E.FYS.FUE=&$O)R!X.GAA<'1K/2=835`@=&]O;&MI="`R+C@N,BTS
M,RP@9G)A;65W;W)K(#$N-2<^"CQR9&8Z4D1&('AM;&YS.G)D9CTG:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R<@>&UL;G,Z
M:5@])VAT='`Z+R]N<RYA9&]B92YC;VTO:5@O,2XP+R<^"@H@/')D9CI$97-C
M<FEP=&EO;B!A8F]U=#TG=75I9#HV,34X93DS-2TT-F8T+3$Q93,M8C0S,2UA
M9F,P83@P93,U-F,G"B`@>&UL;G,Z>&%P34T])VAT='`Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"]M;2\G/@H@(#QX87!-33I$;V-U;65N=$E$/F%D;V)E.F1O
M8VED.G!H;W1O<VAO<#IA835C,#=F9"TT-F8Q+3$Q93,M8C0S,2UA9F,P83@P
M93,U-F,\+WAA<$U-.D1O8W5M96YT240^"B`\+W)D9CI$97-C<FEP=&EO;CX*
M"CPO<F1F.E)$1CX*/"]X.GAA<&UE=&$^"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H\/WAP86-K970@96YD/2=W)S\^
M_^(,6$E#0U]04D]&24Q%``$!```,2$QI;F\"$```;6YT<E)'0B!865H@!\X`
M`@`)``8`,0``86-S<$U31E0`````245#('-21T(```````````````$``/;6
M``$`````TRU(4"`@````````````````````````````````````````````
M```````````````````18W!R=````5`````S9&5S8P```80```!L=W1P=```
M`?`````48FMP=````@0````4<EA96@```A@````49UA96@```BP````48EA9
M6@```D`````49&UN9````E0```!P9&UD9````L0```"(=G5E9````TP```"&
M=FEE=P```]0````D;'5M:0```_@````4;65A<P``!`P````D=&5C:```!#``
M```,<E120P``!#P```@,9U120P``!#P```@,8E120P``!#P```@,=&5X=```
M``!#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD`
M`&1E<V,`````````$G-21T(@245#-C$Y-C8M,BXQ```````````````2<U)'
M0B!)14,V,3DV-BTR+C$`````````````````````````````````````````
M`````````````````````````%A96B````````#S40`!`````1;,6%E:(```
M``````````````````!865H@````````;Z(``#CU```#D%A96B````````!B
MF0``MX4``!C:6%E:(````````"2@```/A```ML]D97-C`````````!9)14,@
M:'1T<#HO+W=W=RYI96,N8V@``````````````!9)14,@:'1T<#HO+W=W=RYI
M96,N8V@`````````````````````````````````````````````````````
M````````9&5S8P`````````N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C
M;VQO=7(@<W!A8V4@+2!S4D="```````````````N245#(#8Q.38V+3(N,2!$
M969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="````````````````````
M`````````&1E<V,`````````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO
M;B!I;B!)14,V,3DV-BTR+C$``````````````"Q2969E<F5N8V4@5FEE=VEN
M9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ````````````````````````
M``````````!V:65W```````3I/X`%%\N`!#/%``#[<P`!!,+``-<G@````%8
M65H@``````!,"58`4````%<?YVUE87,``````````0``````````````````
M``````*/`````G-I9R``````0U)4(&-U<G8````````$``````4`"@`/`!0`
M&0`>`",`*``M`#(`-P`[`$``10!*`$\`5`!9`%X`8P!H`&T`<@!W`'P`@0"&
M`(L`D`"5`)H`GP"D`*D`K@"R`+<`O`#!`,8`RP#0`-4`VP#@`.4`ZP#P`/8`
M^P$!`0<!#0$3`1D!'P$E`2L!,@$X`3X!10%,`5(!60%@`6<!;@%U`7P!@P&+
M`9(!F@&A`:D!L0&Y`<$!R0'1`=D!X0'I`?(!^@(#`@P"%`(=`B8"+P(X`D$"
M2P)4`ET"9P)Q`GH"A`*.`I@"H@*L`K8"P0++`M4"X`+K`O4#``,+`Q8#(0,M
M`S@#0P-/`UH#9@-R`WX#B@.6`Z(#K@.Z`\<#TP/@`^P#^00&!!,$(`0M!#L$
M2`15!&,$<01^!(P$F@2H!+8$Q`33!.$$\`3^!0T%'`4K!3H%2058!6<%=P6&
M!98%I@6U!<4%U07E!?8&!@86!B<&-P9(!ED&:@9[!HP&G0:O!L`&T0;C!O4'
M!P<9!RL'/0=/!V$'=`>&!YD'K`>_!]('Y0?X"`L('P@R"$8(6@AN"(((E@BJ
M"+X(T@CG"/L)$`DE"3H)3PED"7D)CPFD";H)SPGE"?L*$0HG"CT*5`IJ"H$*
MF`JN"L4*W`KS"PL+(@LY"U$+:0N`"Y@+L`O("^$+^0P2#"H,0PQ<#'4,C@RG
M#,`,V0SS#0T-)@U`#5H-=`V.#:D-PPW>#?@.$PXN#DD.9`Y_#IL.M@[2#NX/
M"0\E#T$/7@]Z#Y8/LP_/#^P0"1`F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,
M$:H1R1'H$@<2)A)%$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4
M:A2+%*T4SA3P%1(5-!56%7@5FQ6]%>`6`Q8F%DD6;!:/%K(6UA;Z%QT701=E
M%XD7KA?2%_<8&QA`&&48BABO&-48^AD@&449:QF1&;<9W1H$&BH:41IW&IX:
MQ1KL&Q0;.QMC&XH;LAO:'`(<*AQ2''L<HQS,'/4='AU''7`=F1W#'>P>%AY`
M'FH>E!Z^'ND?$Q\^'VD?E!^_'^H@%2!!(&P@F"#$(/`A'"%((74AH2'.(?LB
M)R)5(H(BKR+=(PHC."-F(Y0CPB/P)!\D321\)*LDVB4))3@E:"67)<<E]R8G
M)E<FAR:W)N@G&"=))WHGJR?<*`TH/RAQ**(HU"D&*3@I:RF=*=`J`BHU*F@J
MFRK/*P(K-BMI*YTKT2P%+#DL;BRB+-<M#"U!+78MJRWA+A8N3"Z"+K<N[B\D
M+UHOD2_'+_XP-3!L,*0PVS$2,4HQ@C&Z,?(R*C)C,ILRU#,-,T8S?S.X,_$T
M*S1E-)XTV#43-4TUAS7"-?TV-S9R-JXVZ3<D-V`WG#?7.!0X4#B,.,@Y!3E"
M.7\YO#GY.C8Z=#JR.N\[+3MK.ZH[Z#PG/&4\I#SC/2(]83VA/>`^(#Y@/J`^
MX#\A/V$_HC_B0"-`9$"F0.=!*4%J0:Q![D(P0G)"M4+W0SI#?4/`1`-$1T2*
M1,Y%$D5519I%WD8B1F=&JT;P1S5'>T?`2`5(2TB12-=)'4EC2:E)\$HW2GU*
MQ$L,2U-+FDOB3"I,<DRZ30)-2DV33=Q.)4YN3K=/`$])3Y-/W5`G4'%0NU$&
M45!1FU'F4C%2?%+'4Q-37U.J4_940E2/5-M5*%5U5<)6#U9<5JE6]U=$5Y)7
MX%@O6'U8RUD:66E9N%H'6E9:IEKU6T5;E5OE7#5<AES672==>%W)7AI>;%Z]
M7P]?85^S8`5@5V"J8/QA3V&B8?5B26*<8O!C0V.78^MD0&249.EE/6629>=F
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MD`:0;I#6D3^1J)(1DGJ2XY--D[:4()2*E/257Y7)EC26GY<*EW67X)A,F+B9
M))F0F?R::)K5FT*;KYP<G(F<]YUDG=*>0)ZNGQV?BY_ZH&F@V*%'H;:B)J*6
MHP:C=J/FI%:DQZ4XI:FF&J:+IOVG;J?@J%*HQ*DWJ:FJ'*J/JP*K=:OIK%RL
MT*U$K;BN+:ZAKQ:OB[``L'6PZK%@L=:R2[+"LSBSKK0EM)RU$[6*M@&V>;;P
MMVBWX+A9N-&Y2KG"NCNZM;LNNZ>\(;R;O16]C[X*OH2^_[]ZO_7`<,#LP6?!
MX\)?PMO#6,/4Q%'$SL5+Q<C&1L;#QT''O\@]R+S).LFYRCC*M\LVR[;,-<RU
MS37-M<XVSK;/-\^XT#G0NM$\T;[2/]+!TT33QM1)U,O53M71UE76V-=<U^#8
M9-CHV6S9\=IVVOO;@-P%W(K=$-V6WAS>HM\IWZ_@-N"]X43AS.)3XMOC8^/K
MY'/D_.6$Y@WFEN<?YZGH,NB\Z4;IT.I;ZN7K<.O[[(;M$>V<[BCNM.]`[\SP
M6/#E\7+Q__*,\QGSI_0T],+U4/7>]FWV^_>*^!GXJ/DX^<?Z5_KG^W?\!_R8
M_2G]NOY+_MS_;?___^X`#D%D;V)E`&1``````?_;`(0``0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#
M`P,#`P,#`P$!`0$!`0$!`0$!`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``$0@`=@"P`P$1``(1`0,1
M`?_=``0`%O_$`,(``0`#`0`"`@,````````````("0H'!@L#!0$"!`$!``,!
M`0$!`0$```````````8'"`4)`P0!`A````8!`P,#`@($"PD``````0(#!`4&
M!P`1"!(3"2$4"D$B,15A0B,647$R)+47=[<8.'B!4C,F-D:V-SD1``(!`P,"
M!`,#!@D)!@<```$"`Q$$!0`2!B$',4$B$U%A"'$R%(&Q0B-T%9&A4F)R0V.S
M%L&",Y,D-387-Z*R4W/4&-&2@S0E55;_V@`,`P$``A$#$0`_`-_&FFFFFFFF
MFFFFFFFFFFFFFFFN!<G<V1_'["MSR0Y%)638LORRJL%1V"4MLOU-(%GT^HG1
M(Z-WU]O4K9%0WTU6?=_N#;=L>W^?Y9+M:\CC]NV0_P!9<R^F%?F`WK?X1HY\
MM6'VLX-<=Q.<83C,6X6LDF^X<?U=O'ZI6^TKZ$^+LH\]1_\`'1GQ[FO!2499
MY-64ON-I(];LCUVMW7TM'NNY(5V>7ZC"H8SMD<[8YA_E+LU!^NJQ^E;N9<=P
M>W"6>8O#-R7$RF"=V-7D1JO!,?/U(3&3YO$QU8GU*=O8.#<^:[Q5J(N/9.(3
M0JHHL;K1)HAY>E@'`\ED4:G[K36L\:::::::::::::::::::::::::::::::
M:::__]#?QIIIIIIIIIIIIIIIIIIIIIIIK/EY5LXDN63:_A6%535B,7HFF;"L
MW<=TKJY3[%,2,E4TCF2`:]!"4/7[R*O52B`=.O,'ZT.XBY_E^+[?X]PUCAU]
MV<JU0UU,@HA`-/U$-/F&E<&E->B_TD\#;"<6R/.+Y"+S*M[<((IMMH6/J!(K
M^NEK\BL2$>.O'^`EZ0XZW>@R]R72:,.34I^YT4R55!,\56X-R_81=W?]:B2"
M#28O[PD6V%01$$4'BG3L!!'E_3-R2/M9R'C5]GI`EMR^;\+&A-#'!"SI'=O4
M@!9;UA;QU_02=Z4"UZ/U"X"3N3@N0V>%0O<<6A_$R,!4232JCR6J="2T=HIG
M>GZ3PK7QUHMUZI:\U]---------------------------------?_]'?QIII
MIIIIIIIIIIIIIIIIIKGF6,C0N(L;73)5A-M%4Z!?3"R11`%'BZ*?0PCD-Q`!
M<R3]1)NF&_J=0-1;FW*\?P?B?(.6Y0_[%86SRD>;,!1(Q_.D<JB_-AJ1\0XU
M?<QY/@^,8X?[7>W"1@^2@GUN?YJ(&=ODIUE?QG3;9R;S3^6N'+E6TY7MLH^G
M99L4SA6(:R;E:5LLL=,"J"1JV07*B0QBF3(B)MP$"[!XS\1P.;[O=P/PDDKG
M,YN^D>:1:L8ED8R7$A'6BJ"%!(*A:U%!37K-RC-XCM;P<W4<2C$XBS18HVZ"
M1D41P1@]/4Q!8@$$M3K4]>B<[L>V7%?()S6GRZO[O1M0I+?%CI)(S=)M18&'
M;P\2U;>O3[^,EHUU[I0NW=>&.ML`J:E7U(<7R_#.Y\V)N96_=<-C:+CF`*A;
M.&(11*OEOCECD]PC[TI:3]/4;[`\CQG+.W464@C'[QEO;HWZD[BUU+(9)&;^
M8\;I[8/W8PJ?HZM!K?E3PS$8NHCFUL;C8,EKUIFG;H2N0J16;&P,2F8O5'$M
M+OH]EV)59M[I$&XN1(DN4#@4P"`;"Q/UG<!L>'<;FS=O?W7+FM%%U%!$-J3I
MZ'+22NB4D*^XNPR$*X#4((UE3)_27S:\Y7R"+$7%E;<76Z8V\LTIW/"WJ4".
M-7:L8;8V_8"RG;44.IG\7>14=R<QN[R)&5=_44&MIEZR:*D)%M*+F-&(1[HC
MP';1!NCLX0D2;D`H]LY3%ZC;`(W_`-G>Z=IW?XI-RFSP\EC&EY+;^V[K(:QJ
MC!MRA1ZED%13TD$5/CJD>ZW;:Y[6<FAXW=96.\D>TCG]Q$:,>LNI7:Q)Z%#0
MUZ@@T'AJ1^K6U6>FFFFFFFFFFFFFFFFFFFFFFFFFFFO_TM_&FFFFFFFFFFFF
MFFFFFFFFJ9/*UFA!1*A\=8E\J569>L[Q??9(F>KMXEJLNVK$9V&RIG!W#M\F
MN\%`4_N!NB;?8VL"_6ES^-DXUVLLK@A[B1;N\V#>RQJ2MO'M4[BS.'EV$==D
M9K0ZVU](_")%;D'<F[@!2%&M;3<=H,C`-.]6%`%4K'N!_3<4J-?V>+_"S.C5
M&W\A;FG&1R<G&+1L#,R+E'IBJRR$7\^]456(FE%IE.@0BR@',!^VH'4!2_?]
M_H][?V_'<'G.Z.?6&)9H3'#*[#]7;IZYG)(`C%0`S5-=K"H`Z_+ZJN<3Y[,X
M;MQ@VED:*4/+&BG]9.WHA4`5,AH25%!2JFE3T@#SEY,L>2&1&+J(C09UNFE?
MQ=666:MT9->-=J(F=.)1<""Z.YD7+8JQ6XG[31/I(`"J94YLS?47W=M^Z_*;
M>:QM?;Q-@'CMR542&-B-S2&FXM(RAPA.V):*`7+L=#=A>UT_;/C=Q#>7._*7
MI22<!B4#J#M$8KM"HK%2]-TC5)(4(HXEQVPX&>\IPF,4Y]I77LX@^<L73XW;
M0=&BT!?O&"2H).#$>JQR*IT0!,_49,0V^NJ\[6<#_P"97,\?P]<G':W%PKLC
M.:!O;&]T!HWK*!BHVFI4C4Z[D\T_Y?<3ON5-CGN8(&165>I7W#L5R*CTARH;
MJ*`ZMO9\B,:>.&=<<;5J'<K7$JIQV07MNC9V+<.%)"U,TF;YNC#29&)O;LQ@
M@Z3"Y*)Q,/V$#6WX.Z?$?I1R4G::3C5_>V15+U[F.:-F+W"A'412!/2OL]#[
M@K4^E=8\F[;\H^IBPC[FIR"RL[L%[-;=XI``D#%E)D3=U;W>HV&E/O'5BF"^
M26(^14(XF,9V0'SF/!/\[KDFW-%V>!,L(@D$I$K&,8$5=OL71.LV./H503`(
M!JCMQW9X/W4Q\M_Q'+>Y+%3W8)![=Q#7P]R(D]#Y.A>,^`<D$#-G/NV/,>VM
M_'9<IQGMQR5]J9#O@EIX[)!YCS1@KCQ*@4.N[ZLC4`TTTTTTTTTTTTTTTTTT
MTTTTTTU__]/?QIIIIIIIIIIIIIIIIIK]3G(F0RBABD(0ICG.<P%(0A0$QC&,
M80`I2@&XB/H`:_C,JJ68@*!4D^`&OZJEB%4$L30`>>LRUT.MR1Y6W2T1*[UZ
MC?+DMCVE+(NFRII!*.;)0+EW%&[J`M8V)A6I3)*&.F/==(GWV.<2^1'(&D[L
M=Z>09FQDDDCR5^;*T(93O"*(6:/J-L<<2@J25]4D;5]3;?4C!K'VR[1X/$WB
M(CX^R%Y<@JPV%V,JK)T.YY)6(8`'TQNOZ*ULLYQNU,'\6*1A2@HIM4K6YCZ$
M99(ADTE8R/CSOI<[A,ASN.B;D"D%R)>X(E5.!@$IA$-;?45._;OLUQWM]QF,
M(EZZ69(%`8T0O*6%2WZYZ;Z;C1F!J"=9@[#0KSSNSGN<\A<L]FCW=#U(=WV1
MT-`OZI*[*TZJI%"!JL'A9QI)R$S&@C:%#O*7"1;FS7HR(JI*N$'"ZS&+AF[T
MG9*"L^YW,8Z>QTVJ:@E]1*8<??3_`-I%[H<\BCS#F3`6\+7%X14%@Q*1Q*XH
M*S-U)7JL:O3R.M4]\.Z#=N>%R/BD"9N>58+6M"`0`\DA4UZ0KT`;HTA6OF-1
M\M<)=.,.?)"-2549V[$5]2>P[TJ8D(_1C'B4C"2"15B`"C&>A5$CB`ATF27$
MH_7589K'Y_M!W+NK1',><P>2#Q/2@<1N'B<5'5)HBIZBA5R#JQ<1?8/NGV^M
MKIT#X;,X\K(M:[#(I25#0]'BE##XAD!U>/F/AGC;G"E5^0U=R39*M(W&AUT8
MP$HZ,FH`6239PY:(NHY4D=)(O&[AZ=)SL[]#IB`%`0'?T4YYV#XG]1"8?NCB
MN67=G=7^-@]NB1RP[`K,H9#LD#*SE9*2>*D`"FL&\+[V<G[$/E>W&2XS:W=M
M99";?5WBFW$A6*N-Z%2%#)^K\#6IKJI2UX]S[X_LT52T/.A!TU>'=U^QP;I=
M2JY`@6CAN,W7G9A*DNBD^;&!-TR=$*LCUE5)U=)%-8CS7%^YGTQ\_P`+F)Z+
M,DA:">%B;:]A5E]V!O`@.M%DBD`=:AUK17UL'$<C[>_41PC+XJ&K1.@6:&50
M+BTE8'VIE\02C=4E0E6H4:E676GFBW")R#2ZI>H(YE(>WUZ(L<:)P$%"M)=B
MB^225`0*)5D2K=!PV#8Q1#7L!QO.V7)^/X7D>-:MA?6L4\=?';*@<`_,5H?F
M#KROS^%O..9S+X#(+2]L[F2%Z>&Z-BI(^1I4?(Z\KUVM<C33333333333333
M33333337_]3?QIIIIIIIIIIIIIIIIIJ$7D!S(MB/CO8T(=TBE;LAJIT2N("H
M4KHR4L4P6)ZV3ZR',9C``L!3!_)652_$1`!SS]3G/).#]K,K'83*,YE"+.!:
M^JDG^G=14$E(=]"/!V3S(!O7Z=N%)S'N1C7O8F.&QH-U,:>FL?\`H58]?O2[
M:CS56^!(C%XW..WMVK/.UGAG+!..B?W8Q*BZ_9'?1CAJ8ELO3E$R9%W`6-\I
M[>/,L`"BP;$`FY#%,-/_`$G=K/:B@[D9C'O$D4'X?&ANA>-EI<WC"@+>^YV0
MEONPQJ%JI!U:GU-]R1)+/P#%7J2/+-[^0*]0KAJV]JIJ0/94;Y@OWI7.ZC`C
M74_)-72R5+Q)/+H.!9UW(W2Y?(,`?DC22T6JDJX=IBJF!6HLFJX#N'28_2!C
M$#<P3/ZL\6MWQ_A&2EC?V+7*T9PF\()(R"S"H].Q7'7H30$J.HB?TQ9(VN<Y
MACXY%]^YQGI4OL+F.0$!30^K<R_.E2`QZ'Z'QE1",9`Y=(=DW;/6<]58(BJ3
M?L]R-AH=X@BB!CI$46!J_.Y2,<#*$,8GVG,'W#S/I#L8[/&\Y5K=4N([FVAJ
M%I6.*)U`Z@$[7+J35@2.C$=3T/JEO'NLAPXK.S0/;SRT)K1Y9%)/B0-R;&`H
MI`/4#P'C/D(X37[.5UJ&2L-0D7)V-6)7KEZ9O9B,@2KM8PP.*Y,E<2*R)';I
M--PNT4*&Y@2(C]"CMR?J@^GODO<7D&"Y;P+'PS95H#!>*\L<-5CZP2[G(#,`
MSQL!UVB/R&NI].??/CO`\'F>,<VOI8L:)A-:LL;RT9^DT=$!*J2JR*?#<7\S
MKOG`'&6=<,XKF\:9HA&$6T@[$I(4-9C/Q4[U1$X51Y+QJAHUPL+8K&:!19,#
M@'4#L0+N!=@LOZ9>(=Q^`\,R'$>?X^*&"WNB]F4FCF_535>6,^VQVA)=S"OC
M[I`\.E>_4/RG@/-^6V/*.$7TDLT]L$NP\,D7ZR*BQN-X&[?%133P]NI\=?;>
M0REUZW\3\HO)M%$'=)C4+K77ZA2BK'S4,Z1*3L'$!,7\R9.5F9P+ZG(X$/4=
MM?M^J/C^+SG93F,^11?>Q\2W<#FE4EB84H?+W$9HC3Q#D:_'].&<R.&[O<4A
ML';VKZ4VTR#P>*136H_F,%D!/@4!UUOBM69:G<<,*5N<15;2\9CJLDD&J_\`
MQFCAQ'I.S-%@W'I5:@X!,P?JF*(?34W[,8B]P/:CM]B<C&4OH<5`'4^*LR!M
MI^:[J$>1%-0_NUE+3-=S.<Y.P<-9RY*<HP\&`<KN'R:E0?,&NN_:LW5>::::
M::::::::::::::::::__U=_&FFFFFFFFFFFFFFFFFJQ\AXV1Y>\H[+5K,$NO
MB'"%?1A/>1#Q-I'FO$U[9[*-/<'1.X//)'1*18J(F33;M$NOH.8O7D'E'$X^
M^?>/+X;+B=N#<=M1#OB<*ANY=KR+NH6,P(`<+4*D:;MK$;M3\<Y._9KM1B\M
MBS"O,L]<F7;(I9_PL6Y4:@(`B()*ENI>1]NY0=ME,7&,86,CX>+;)LXV*9-8
MZ/:(ATI-F;)`C9L@F'KL1)%,"A^@-:ULK.VQ]I:V%G$([2&-411X*J`*H'R`
M`&LP7=U<7UU<WMW*7NII&=V/BS,26)^9))UXGDNA0^3*5.4V<:-WC.5:B":3
ML#BV*]0$%F2C@J?W';E<D+W"AOU)B8/KKB<NXU8\NX]D<#D84D@F3H&KMWCJ
MA:G4KN`W#S6HUU^+\@O>+YRPS5A,R30OU*TW;3T8"O@:5H?(T.H4<7@'%&3K
MQCJVOC-I69(Q]N63$&2_YC&"JWZOYPBR_-V5A*8SEI(I$[+I8R@`"1E2(ESY
MV='^"N7\BXKF[DI>W`3;[GH.^.J_I!/=2?K)'.HVR.7%$+K&+T[K4Y?Q7`\E
MP]N&M("U=GJ&QZ'R+>VT/1)(6.Y%VFK!&<V):U/K-FO@=."-&SATH!A3;(*N
M%`(`"<2(IF4,!0$2@)A*7TW$/77SFE6"&69P=J*6-/&@%>FOI%&TTL<2TW,P
M`^TFFJ6\J^2+CYE<8&JS]0RL7'$?.1]EM422%JQW]R?5F3:R=;K+M,]L%LUJ
MYI=JF\D!ZSJN0;)M@*5-14X8`YI]6':_FIQF&R6#S7^%(KA+BXC]JW+W3V\B
MR06[`W.U;?W5$LQJ6DV+$`%=VUM_B7TR]QN(?O#+8_,XC_$TEN\$$GNS[+9)
MT9)IU/X?<T_ML8X10*F]I22RH-=@2\M''Y91%NTH>8W"RIDDDFZ%?JIU3J*&
M`A4DDD[B8ZB@F$`*4H;F$=@U.D^MOMA(T<4'&\\\C$`*(+<DD]*`"ZJ3\`/'
M4,;Z0.XB*\DW(,*J`$DF:<"@ZDDFVH!\3Y:ESACDE'9M:#*0N-<DU.(,Y!JU
MD+['P5>_,5#$34(>.9A/O7SQNH14.E4B8IF'<`,(@.KPX#W9M>X4/XNPXEEK
M*Q+[5>\2&#>:`@HGO.[J0>C!=IZT/35.\W[97/!9OPM]R?&7EX%W,EH\LVP5
M((=O:55(IU4G<.E1UU)+5LZK'3333333333333333337_];?QIIIIIIIIIII
MIIIKX'7N/;./:=KW?85]KW^KL^X[9NSWND0-VNYMU;"`[:^<WN^U+[%/?VG;
M7PW4Z5^5?'Y:^D7M^['[U?9W#=3QI7K3YT\->#8SH++'%4;0#=<7\@X?2T]8
MYI1,I',[9[%)NYN?EE]@Z@*YE'ZO9((F[+<")`/20-1SB/&;?BF%BQD<GNW3
M2233RD4::XGD:::1OZ4CMM!KL0*@Z*-=[E/(9^39>7(R)[=NL<<4,0/IB@A1
M8H8Q_11%W$4W/N<]6.O.G)5SMUR-5DV[HZ*I6RZR(N4D5S$,"*RK<JS<RZ::
M@@)B`H03`&W47?<)'*)&BD6%PLQ4[21N`-.A*U7<`>I&X5\*CQUP(C&LD;2H
M6B##<`=I(KU`-#0D=`:&GC0^&J7>0W-WFEQMN:]6O&/,0K13IPY&J7)G7+H$
M!;8](>HB[)8;L<K6220$HN62AA6;F']9,2J&P#W1^H;Z@.TV?DPW(N+8)K)V
M;\-=+!=^S<H/-#^+.V0"GN1$[T/Q4JQV_P!N.Q78_N;A(\M@>29E;M%'XBV:
M:V]ZW<^3#\,-R$UV2@;7'P:JB*5P\EN7[XS3:6;&V&GAVQNY'2;:)NT=.0Z^
MX&*ZAIMC>$)*,<%.4#=22A0$0#<!U2V=^K?G7)8$@R_$\`[(:I(L=VDT1_E1
M2I=B2-JT-58>'6NK<POTO\,X_,\V+Y/FT5Q1T:2U>*0?R9(FM2CCRHP/CTIJ
M2W#+GEF_*F<<?X@M:53<U:>)92NG96$JI8$2Q%6F9IH5"4<S*X'_`)W'$*;N
MIJ#VQ$H;>@A;?8+ZDNX?,^XO&."YI+)\-<BXW-LD,X]JWEE6DC2G])`#N5O3
M4"G0BK^]OT_\$XGP+D?,\0]XN6MS!M7?&(3[D\<35C6,4]+DC:P]5":]:W92
M2"CJ.?MD@`57#)T@D!AZ2BHJ@HF0#&^@=1@W'7H1=QM-:W,2??:-@/M((&L,
M6LBQ7-O*_P!Q74G[`03K-:EXO^6BY%53P=$:G]T)"H+WIJ94Z2@G.+DIFS!P
MB"9/0!*)@.(CZ%VUY+)]'G>Z17=L=C4;?3:;Q:D&OJJJ,*#X5K\!KT[?ZJNS
MZ,B"_P`@R[/$6K4J*>GU.#4_&E/GJ:7&_P`>-@@'2?\`732,6*LXF75=-%PD
MI*VR$@U69B`D3(1M#@DF#[U`'#@_:#8R9`,'I?\`VH^EO*8R9?\`F!Q[#-!!
M.64^Y)<NZE/``+%0;^OK<[?%5KX4CW,^I#'9&%O\#YW+"::$*PV);HC!O$U:
M2IV_R$&[P9J:MDK-+K-0:MFE?B&48DU9A'H%:)"F1)F#A1U[5$@G.5!L#A4Q
MP(78H".MLXCC^(P4,4.+L8X42/8-HH`NXMM`J:+N)-!T%=9!RF<RF9EEFR-X
M\K.^\[C6K4"[B:"K4`%3UUY3KLZY.FFFFFFFFFFFFFFFFFFO_]??QIIIIIII
MIIIIIIIIIIIIIIIIKG&5<3T/-5+E*%D6";SM?DR;])_V3Z,>D*8&LM#/RAWX
MV69'-U)+)B`AZE,!B&,48IS3A/&NX&`O.-<JQJW.,F'GT>-Q]V6)_&.1#U5E
M^PU4D&3<1Y?R#@^<M.0<:R#6^1B/EU1U/WHY$\'C8=&4_:*,`17H'B/X^A_W
MSEX?TC,5/?\`V_\`)P:R[_[(.V'_`/1YS_6VW_I=:._]XG<7_P#0X;_5W'_J
M-=4PIXZL.X+R96\IU:UY&DIVL!+`Q93LE7G$4M^<0TA"./=),:VP='[;61.8
MG2J38X`([AN`S/M]]*_!.W'+L3S/#9K*RY*S]W8DTD#1GW8GA;<$@1C17)%&
M'4"M1TU$N<_4GS3GW%LGQ/+8C&18^Z]O<T23"0>W(DJ[2TSKU9`#53TKX'KJ
M?VM-:SQIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIK__T-_&FFFFFFFFFFFFFFFF
MFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFO_1TI^8?ROQ
MOCIQ_`5*@1,5;^2&5HJ7=TF+EU04KU!KL>HFR<Y#N#!!5-[(MQ?JF0BF!3)%
M?ND%A.H5)NH4]G]MNWK\TO)KF\D:/"6[`.1]Z1CU]M#X#IU=NNT$4%6!%/\`
M=GNA%P"Q@M+&)9>172GVE/58UK3W'`ZFIJ$7H&*L2:*08X<'O'QRSY%X@D^2
M'.;FKR.5R-R0PQ;X6KXUJ5L+7Z]B"F9;C6#N'LC2&;I?D45D%JR*D[:H,&;-
M"**J"!^XJ!^CL\JYAQ["Y%,)Q7C-D+*RN4+RNNYIGB)#*6^\8ZU4EF8M0D4!
MZ\+A?!^49[$/R#F7++XY#(6K!(D>BPQS+56"GTK)0AMJJH7H&J11:^8'GUS4
M\,_-@O%?F3EBR\H.,LL$%,1EUMJCV:NS#&ED76C8G(U,FI5X\GRN*T[C'#:7
M@'KMXU,=FX!H8ACHK'F4W$.,=S.+'D'&L>EAG%W`HE%0R+U,;J`%]0(*R*`?
M4"U0"NH#!SKEW:/F0XORW)29'CSA661]SR")^BR1LQ+U4@JT;,RDJRKU(D.R
M:#FXBRPL/8Z_),YF!L$7'S<)+QRY'4?*Q$JT1?QLDQ<I"9-PS?,UR*I'*(E.
M0P"'H.LTRQ202R03(5F1BK`]""#0@CX@]#K6T$T-S##<6\@>"10RL#4,K"H(
M/F"""#\-8PO.%SVYA\6?)%&QN">0.1*-5:YBS%%N;8]:3CAQCJ3F%7UB5D`G
MZ8Y%6%EVDT1FFD\(JD(JI!^("!3!IOM7Q#C?(.%.^6Q$,MP\\J>X5'N`>FFU
MQZ@17I0]-9"[T<\Y7Q;N#!'ALU/#:);PO[88F,GK7='78U:=01U\]:O^'_(F
M&Y9\8\*<BH)H6-;94HL78'\243&)"61(58JVP29SJ*'51A+3'O&I#F'J4(B!
MAV$=M9[Y)AI>/9W*8:5MQMY2H/\`*7Q1O\Y"I^5=:AXGGXN4<<P^?A4*+F$,
MRCJ%<5610?,*ZLH/F!75<OG?YGV[A]PM,7%-S?4?,V:+O#X^H\_"KF;6.!AV
M95+'>K'".@*;V;IE"1Q&)7`?>@K)IG)L<`,6:]IN,6W)>3__`)"V$N,MHFD=
M6ZJS'THI'G4DM3P.P@]-5]WMYC=<1X>6QETT.6NYECC9?O*H]<C`^70!*CJ/
M<!'7J(\_'+Y%9[Y&X/Y'V#/>7\@Y?F*]EZN0L!)7^PO+"YAHM6D,W[B/C5G@
MF,V;K/%A5.4H["<0$==CO3A<1A,MAH<1CH;>)[=F81J%J=]*FGCTUPOI_P"1
M9OD>"S=SF\G-=31W"JID=G(&TD@%B2*^?Y-7(\R.6.-N$_'F^\A\HBY<P=/:
M-V\378Y1%.9N=MEU@8UFH0@K[I%?S4B<I3*F`R;5L55PH';1/JM>-<>ON49F
MTPUA02R'JQ\$0=6=OD!Y>9HHZD:MKEO*,=P[`WV?R1)AB'I4?>D=NBHOCU)\
M30[5!8]`=9>.'<%SH\[=_P`I98SER9RGQZXD4:R$K\=CG`TXZJ+&4L"Z!I9M
M3(!9$R:,HK585^V5E)N92DG"JCI%-%(@&,#>^.2R\4[36EACL5@[>\Y%*FXR
M3J'(4&A=O,;V!"HA4="2>GJS;Q"/FG>R^R66S'(;FPXM!)M6*W;8"Q%1&H^Z
M2BD,SRJY]2T!KZ+L..?C4S!P_P`SXYLN$N<O(.\X";NIQIEO`7(NQ-LE1\W$
MOX"02B9.A3R43'A5)Z+M'LW"H)M4O<MB*$%<`$2*5?FN;XWDF,O8,IQ6SARY
M"F&>V4QE2&%1(I8EU*U`JQH:>GS%QX#M[EN*Y:QN,1S*^GPNYO?M[IA(&4H0
MIB*JJH0^UC1`3U]=*JTDO)E=KEC;@)RPON/+3.4F[U/#=GFZS;*T^4C9V!EF
M2:*K9_&/TOVK5RF("`'+Z@`CMKB<'M;:^Y=Q^TO(%EM9+E59&%58&O0CSU(N
MX=[=X[A/);^QN'BO(K5F1U)#*13J".H_)K-;XC(#FKY+,9\AYNU^2_F)C"U8
MJGJG`4UQ6[HA+P+AQ:(&:DA>6>-DDDI230:NXU,H)-WS,12$P`<#"`A=_<:7
MC'![[#16_",;/;W"NS[DVL`K***1T%03U*M]FL[]J8N7]Q,9G+BZ[@96WNK9
MD6/;*S)5P_5P6#$`J.@9?/KKZOC[Y-.=_CO\@3CAESNR@]SUCASD*MT.?L]J
M62=2\!&7I2++2LO4JVN&K:97K2S*5:NWT9)&<`5J9<A>RZ3ZA^F8X+Q/F?#E
MY/Q.Q%I>B%I%510,4KOA=`2NZH*JRTZT/53KXX/N1S7@7/&X?S6_-[CS.L;.
MQJRJ]-DZ2-1BNUE=E8D;:@`/UUM,UF'6P-9H/+YYA,GXARU'\#N#S1&0Y'V=
M]5*U:<B)(1<TK3;!?5FK:N8_I,6^!U&+9`D4Y)JHY>/DSMXI)TF!4S.1,=M>
M/;CMM8Y+'/RWE+$82,.R1]5WK'7=(Y%#[8H:!>K4))V]&SIW7[M9#$Y2/A'#
M5#<AE9$>4;6,;R4"Q1@U'N'<M6;HNX*/54IW&H>(7D(^XP9`J^4?(?R4E.5>
M4)C&V0W.7&-XL2\%CNZXS8W8D#5JF@>5;V(U*=J7A5*6,B\9'?"S;JHI-P2*
MB/*N>XV&7.V<]APVR7C]NLD8B,:AI$E,>YG])7>/;&RJMMW,"6K77<M>U6=?
MCN0@R/.[]N3W+12>\)'*121+*%1/4'V?KB'(9=Q1&"KMIJ!OC6\M/)3"G+=]
MXY/(G82W"79Y`D,0U;,,V[;'LE;R"V=KMX&&M=B*D@%VJ5]<';IQ4JY#WZ2K
MUMWE%4%-T);S?MWA,IQU.:\,A]N,PB9X5!VM&0"S(OZ#QBI91Z2`:`,/5!NW
MO=3D.'Y4W;[GTWN3"<P).Q&Y9-Q"AW_K$D-%5SZJE224/IUP:SMK5&LDG('R
M1<P?)%S9=\`O'/>TL'XWK\U9XZZ<@8I58+-.0U&<>UN%X0G6Q2R%;H[*0*5G
M%-HSL24NY72%1TDBN!$M$8?A/'.$\67E_-+0W5ZZJ4MS]U6<52,J>C.1U<O5
M4`-%)6IRSG.X?*NX/,CP7@-[^#QZ.XDN5)#LL?1Y-P]2Q_\`AA*,Y*[FH^U;
MUN"GCWJ'!N.MKF+S5GG-=YR0C%JY&MF8+_(V-C.3$4HZ50E8:K+&585Y4IWZ
MY0/W7+LZ2G0LX6Z2"6I^5\QN.5/;A\9:6MK"3[:0QA2H-.A;Q;P'2@6HZ*-7
M;PS@UMPZ*X*9>\O+R<#W7FDW!B*D$+Y4J:$EFH:%CJ.W*'"N?;3R22M4+!7.
M?4).F4QI.0`.SQ4177%#A8NOL8^RED4XG$DIC_*;9[/S#AXD@I8(]T5%LNNH
M3VJ?;P&4P]OA#;RRQ(-GZU6I4M[C%B5INF$D16-`I(C858`>HQGDV%SUUR,7
M4,$TAW_J66NU4,2J@#UVP-%.&ED+`&5&HK,1L'__THX<O,B/^<7F.F6\RJX?
M0%HY:T/`-9CG2HND&E`J.18?&C-DU2`!31:RQ&;I^HD0-O</U1'<QC&';7'+
M).*]M(VBH)H\<]PQ'0F1HS*2?F*A:_!1KSRY9DGYGW=D2<,UO)DTM44FH$:R
MK`M!Y!@-]/BQ/B=>R$33323(DD0B221"IIIIE*1--,A0*0A"%`"D(0H````;
M`&L3$DDDGKKT,````%`-9&?E1XSB1@^(F94&)23B<WDG%TM(E`>IS$.XZ%ML
M`R7'?IZ6#V/D3I?7=R?6B^P%_()N18QF_5%8Y0/@061C^4%:_8-93^IW&1&U
MXQF%6DRM+$Q^(]#(/\W]81]IU9]\?[-DKF3QK8O83JRCJ4PQ:;GA4SQ=RJZ<
M.HBL/&LY5@5,L)CIECJK:63),@")2I-2[;!Z!`^\&+CQG-[]XA2.ZC2:GP+5
M5OX71F/S.K+[%9J7,=O,:LS5EM)'@K\EHZ#Y!4D5`/@HU0KY\\0R67_)'>F,
M*H=.1H/`UOF,4$4"JFDF&,Y.Y34ZU/ML8`)7`=+=8>I>P&_V[ZMSM#DTQG";
M1I5JDV6,/V&01JO_`&J#\NJ-[Z85\SW!OUB?:]OA5G\/$1&5G_@0,?R:LJ^,
M9R-)>>+V5>-TJ\!2;P1D`+-7&YP,!QQ_E8KN4331$3"54L?=XB7,IML)"O$@
M'\0$8/WVPAM,]C\W&OZJ[AVL?[2*@_C0H!_1.K#^FWD(ON,Y/CTKCWK&?>H_
MLYJFGS(D5V/PWC5>'R!KC.\F>95TQ'7WSM*E\$>+KS)=O`JONH_][;Y,TM=\
M)$B;)M'#YK;:LQ,8^YP%-0`V]`U,NSUO%@>-6N1F0?B<M?>VGD=D:O3[:;)6
M_*-03OQ<R\FY9=XB"6EKA<?[LGGZY&C+?(5]V!>O6HU.WXLW^6CD[_;S"_W=
MP>HGW\_W[@_V1O[PZFOTR?\`#/(/VQ?[L:C]\IW-#HTKQ3X[-.^DQ18W3-D^
M(+?S9XY661HE2(+</458]-*:-U&W]'``&VP[]GL#BUV9_--]^J0K\@/6_P##
M5/X-<#ZG<P]>-X!/N4>=OF2?;CI]@60'Y-]NKL/")C%CB[QB\7FC8I?>7:L3
M649E8J94S.)'(5GF;"B*G2'[0S.'<M&P&'<3%0#]`!5O=._>_P"=9UF^[$ZQ
M#Y"-%4_PM4_EU<_9O&1XOMSQR-#5I8VF)^)D=F'\";5^P:M>U7VK/U7[Y6/_
M`)O\TO\`3[D#^B3ZF';_`/XVXQ^V1_GU!.Y__3[E_P"PR?FU1]\5;_U=S(_M
M%Q-_XI:M6K]0'_W_`!K_`,F;_O)JF/IB_P!T\H_\Z'\TNJS_`#G0"V=?,6TQ
M'CA-O(7*>B>.F).AJ(..JZV845F23L&H'5*HQCK2R%8/4Z:9!WVZ?2<=J)AB
M>VSY*^JMJC7$W7IZ$K6E?B4:FJX[V6YSO=B+$8\AKQUMX>G7]8X7;6G]-0?A
M36ZC)=W98;P[?LCRQ#2$?BO&MINLBEW`0._:4FL/IQTD"I^L$CNTHPQ0,._2
M)M_764;&T;)Y.SL8SM>XG1!\B[A1_!76U\E>IA\1?Y&4;H[6V>0^51&A8_PT
MU@$\+)9?DIY@,89-R,Y5G[&^GLT9[LSV0,+M9W:CU6SR;9ZHHKU"*C.S6!NJ
MD;]3M%`NVP;:^[GF+!]M[VPLE"0A(8$`Z43>@I_\@(/VZPIV>6?D7=JQR5_)
M[DWNSSN3UW/[<C`]?[0AOMU[$;6,M;]U@$^1]CI'&_D=;WFO)&AGF5,,8XR&
MM(Q_6U5&UUV3L-%-*HK)"0R<D@SIC`PG((&`Q2'WZA$1V!V3O3?<):TF;<MO
M<RQ@'KZ6"R4^RLC?FUA'ZAK!<;W#COH$V-<VD4I9:@EP7B/4>!VQ+U'7K76T
M?BGE>8Y,<*L(Y;3<_E]IRU@.K3;MX58Y@8W"8J*+:6=$7(`*=#:Q@L<I@^X`
M*'UUF'D&/BP?*,KCB-UO;WC`#XH'J!^5::V)QC)S\BX;ALI7;>75BC$_"1DH
MQ_(]=8;_``@<BJEPR\CAHS.C@*E'9`@;OQSL4_-F*S:TN[OKA7WT:XL2SP4Q
M8,7%KII8QRN<2E;'>%45$J1%#!JONIA;CD_"1)B1[CPNERJKU+H$8$+3Q.Q]
MP'G2@J2-8K[+9ZVX?W$,.</M+/%):LS=!&[,C`N3X#?&$8_H[JM0*=>Q#`0,
M`&*(&*8`$I@$!`0$-P$!#T$!#6,M;^\=?G337__3AIPN:*D\ON"F4X4%':'.
MM!.0!T(&$TDURQ)"8ZACF-U+!()`8H[B(G`!W$=;DY.X/;?*O#T4XHTI\#%_
M\-><_$4([N8=)^KC+QUK\1,O\=?X]>S#UAO7HQK+O\I:5:H<8^,T*<1]Y)Y\
ME9%L'IM[>'QU8$78C]?0\NCM_'J^>P<;'/9R7]$6@'Y3(I'_`'3K-'U-NO\`
MACC\7Z?XUF_(L94_QN-=)^,(T>(\$,J.ERG*T>\H[H9B)A'I.#?&^*6[E1,/
MP`.\3I$?J)1_@U^+OPR'EN/4?>%@E?\`6S4UT/IJ1UX/E&;[C9)Z?ZB"NOX<
MMUR'N/R-:)4+$S2D:_:N`UOK<['+E*H@_AYR$R1&2;)8ARF(=)TR='(8!`0$
M#>H:_N.GEMNR]U<PMMFCRZLI^#*T1!_(1K_64MX;SO[;6EP@:WEPI1@?`JT=
MR&!^T$C5,OB@GY/QW^9"U<=+Y(R<=!R\UE+C=-?LU523:K=P>QXFF56+413<
MJ6!U`Q_M#E*80"6V)L!S`-G=PH8^9]M+?-6:*TJK%<K_`#>FV5:GPVAFW?T?
MEJGNUT\O`>[EY@+^1UA=YK9J_I=:Q-M'B7=(]M.M'^!.I"U>J3.7O&+YE/(U
M=V3HECY=9#&-HIY+MB]C<54+,5:38QZ)2%W:H)RK_P#+#I]0AM!);!L4#&XE
MQ<1XWG/;;A=JP]G'0UDIX&5X7J?GT&^O]H=2.UMI<MVY[K<_NU;W\I<*(ZTJ
M(4N(S04\`&81D5_J1\-35^+-_EIY._V\PO\`=W!ZC/?S_?N#_9&_O#J6?3)_
MPSR#]L7^[&JWOE!D>!S?PP=3?V9^+D`5GOU;=XF4<H>\V$1Z=]CI;[>O\/TU
M-^PQ3_"N3`^_^/:OV>U#3_+JN?J7#_XSPY/^C_=T=/M]Z>O^35K?%[`'E1R+
MQ/XE6KBESQQE@K"KOC%A1I`XWL>#JK>9:*EXZEL&=E>KV.5K$F\=DE9A)18A
M!5$$2FZ```#5>Y_+\!LN1<B@Y!Q.:[R8OIBTBSN@(+DJ-JNH%%H/#KXZMCB^
M"[D7_$^*7''.9PV6+..MPL30QN5(B4-5FA<FKAC][H"!3IJ;_%7C7Y5L?9_K
MEWY3\\*!GK"K.$M+:>QO7,71%!>OIN1B1:UV005AZDP350B9`"K&(9RD`[B(
M%,/H,4S^<X#>8B:UP'$Y;3)EEVR-(T@`!JP]4C>(Z>!U,^-<>[DV&;M[SD?-
M(KW$A6W1+&B$DJ0I&R%/!J'[P\#T-==S\K'_`,W^:7^GW(']$GUR^W__`!MQ
MC]LC_/KK]SO^GW+_`-AD_-K*MX>LB\DL0>-_R:Y6XIJ5@F6<<6#%5R*%I@#6
M1(*;!5:TO+R[A(PSMNR5LL/62.'[,':;ILH=J*1T#BH&V@.Y-EA,ES;@V/Y`
M)/W?.DJ>EMOK9D"!CX[6:BFA!%:U%-9D[29#D&)[==P<IQGV_P!YV[0R>M=W
MZM1,9"H\-RI5Q4,#M(VFHU)OXXM0P-R&RGR(Y(YE-)9-YOU*XIVIK;+W-$FA
M1JN0V*B;N_5V%60(!;:I86S]D]DCF6,S:KMD6P-BJF!7A=Z[C+8:PPV$QFV#
MBLD6PI&-M6C/2-F_D;2I5>FXABVZ@I(OI\ML+R#(Y[D.8W7',XIMX>1MU$D\
M752/])OW!FJ=H90NTL:Z3O(0B\<<#^9B+`%!=J<7<Z@D5(1!0VV-+(*A";>O
M4=(#``!^.^J1X:57EW&"_P!W\?;_`-ZNM#<_5VX+S%8_O_NRY_N7UB^^->DR
M5\CP*.>V+A#CWE%6.ZS`!O<GDZ2BKV@_6/[%57</]W<=:<[WEAPH;?`WD5?L
MH_\`EIK'OTZ`?\PY-WE934^VJ#\Q;^/7L`M8^UO#6&?Y14PR=<Q\!0B(D%[#
M<;47CX2D$%"IS62[J5DFHIU"!@`(E0Q2[`)>L1]>H-M6]A(G7C>7F/W&O2!_
MFQ1U_/K%'U-3HW*L+;BGN+8*3\?5+-3\VM-WAW:NVGC&X9(O0,58V'8YP4#@
M)3`U>2\P[8AL(C]OL5T]A^H>NJ)[D,K<YY*5\/Q)_A"J#_'76ENU2LO;WBV\
M]3;U_(7<C^(C5&GG8\-D_89N\\Y^+4`XG7<H1S9>1.)(M`SB3<.&[;KELLTA
MDF!E9%5PW1[L]&)E%8YRG?(@<QG!`M?M-W,A@BM>*9^8*@HMO*?"GE$Y\OA&
MQZ4HAI1=4CWM[0SW$UYS;C$):8U>YA7QJ.K31CSK]Z11UK5Q6K4^;P#^6ZY7
M&S5O@?R1L3JT.'D2[1XZY+FG2[R?.:"8*2"N);3(+BJI*((P3-=>">KG[R1&
MQF)S*`9H"?\`.[_;JVM8)^6X2$1J&'XB)11?4:>ZH\O40'4=#7?THQ/^NQ7=
M:[O;BWX1R*8R2[2+:5JEO2*^RY\QM!,;'PILJ0R!==^LY:U;K__4XMSZQK)\
M!?,3(W*0:.8VH-^1]$Y3TJ1$![+VBV3(#&]2QF2B0%$Z<%.-Y6-,3;K`6>P[
M@8!-M+B%^G+^VJVR,&N39/:N/@ZQF,5_I*5?_.UY]\YQ;\&[NF\=66T_>$=Y
M&?'<C2B;I3R#!H_C53KV*45*1TY&1TU#OFLG$3#!G*1<DQ6(Y92$=(-TW;%\
MT<)"9-=J[;+%43.41*8A@$/0=8PDC>*1XI4*R*2"#T((-"#\P=>@$4L<\4<T
M+AHG4,I'4$$5!!\P1U&L7?RC,X-;+FKC5QSAU$WKG'-*LV2K$W9&.X=DF\F2
MC"OUN*6;I]0@]3B:8LNFF`=PQ'Y!VV,7?3O87%&#%YS-RBBS2K&I/\F(%F(^
M1+T^U3K'OU,9D768X[QV!JO!"TK@?RIF`4'X%5BW4^#@_#6BWQ(\5Y7A]P+P
MEBJUQHQ.0Y6.D<DY,8',H*[&ZY!>GG7,2[(J1,47M<AE646N0`Z059&V$?Q&
MENXG((^2<MRF0MWW6:L(XCY%(QMJ/DS;G'R;6@^UG&9.)\(P^,N8RM\RF64'
MQ#R&NT_`HFQ#\U/CXZKMMSE);Y+^+$4Q,)V?"B617`2B``HI&7MR4"C^L':7
M*._\/I]-3*W!'8^^)\\F#_'&/\FH'=&OU#8^GEBJ?]B<_F(U4Q\AG"MQP%Y#
M\/\`*7&:#]E)9HC*3:*W)1R(MS(YMPO+0<(1LS7;&*H9\XBDZZX`1Z3G44/^
M.PCJQ>S>4MLOPS)8"^(,=JSHP)_J9@S=:^53(/A0#54]^L+=X/G^(Y-C5*R7
MBHZL!U$\!5#2GFJB%AX$LVK[O)CC.!Q#X5N1U(KM/8T!JACN,L<G3HQV20CZ
M_:[WF2MWJZQS-\FFBF\:HV^QONVH4I2F)ML`!L&JAX1?S9+N=AKN:Y,S&9E#
MD4+)'"T:$CR.Q5KJ\NX>-@Q/:#.65O9K;J(4=HU-0CRW*2R`'S'N.U#\-0B^
M+,<H\:^3Y`,`G+GB#,8N_J!3X\A>@1_0;I';^+4K[^_[\P?[*W]X=0OZ9/\`
MAGD'[8O]V-<Z^4=QWD9:H\<>4L)%O73:FR-AP[?WZ!#*MHR*M)VUCHCMX!"B
M+5M^?,9)KWC"!!7?(I^ACE`W[>PF:2*YS6!ED`:4+-&#YE?3(!\30H:?!2?+
M7.^IGC\L]C@>201L5A+0RD"M`WKC)^`!]P$GI5E'B1JS3P%9NC<P>-3#D*G(
M-W5BPG(6O#MH:)FV<1YX"<=3%6*X2,(G`'%'GXTY3_R3CU;>H&`(+W>Q3XSG
M&2DV$072I,A^.Y0KT_\`J*VK)[&YN/,]O,5'[BFYM&>!P/*C%T'^K=/EX_#5
MS^JQU;^J^O*VH1+QN\TC''I+_A_OA-]A'[E(T4R!Z`(^IS@&ICV^%>;<8_;(
M_P`^H)W/_P"GW+_V&3\VJ-OBRL&,KB#FK&2;-K(QLC>\7,)"/?-TG3)\Q>4Z
MVMW;-XU7(=!RU<H*&(HF<HD.0P@("`ZM;OZ[QY+C$D;%76*4@CH00R$$'R(U
M2WTS1I+AN5Q2H&C:6$$$5!!$P((/B".A&JVZHM)>%GS6G@G#Q>$P/-7,D*[6
M<N')8N0XSYK?)J0\@^.F5HB^-C"1,BJH/2)"O:^H'X".\VN`G<_M>)54/EDB
MW"@ZBYA'4#QI[HJ!_-D&J[MFD[/=XS"[E,))-M))Z&UG/1B>E?:%&/QDB(\M
M;P+W4(3)V/KE0IA05JYD*G6&HRBK0Z9Q5A;9"/(9ZHV4^](XG8OS"0WJ4=P'
MU#63+2YEL+RVO(A2>&57%?Y2,&%?RC6W+ZTAR>/O+"8UM[B%XVI_)D4J:?D.
MO7Z>)TDIPB\RE`Q)E\2UR6AKQE#CA8U'JI$FYINQP<O!4]=-P82HK,K-9&\2
M9HJ`]"R;Q(Y1$#!K8/<+V^5=L[O(XWUQM#%<+3QVJRL]?@53?4>1!&L(=KC-
MPSN]:8K+4CD%Q+;/7H-SJ\:4^(:0H%^(((J->P]UC36^]>O4\P4O:><GE]M6
M%\/L#6&P1LUC_C!2F[<YUTEY^"1,K:WKM1(BI6<;`VN?E!>J@`D;M6"BI]ND
MVVR.VT=OQ3MO!D\D^R%DDNG^2M]P"OB614H/,D`:P1W:DN>:]V9L1B8?<G1X
M[5*$D$IT;=2NT+*T@8_HJ-QZ#6]K".+(+!V',68:K!`)`8LQ]4:#$B'5NLSJ
MD$QA4W2@G$QS+//9BJH8PB8QSB(^HZR-E<A-E<GD,G.?UUQ,\A^UV+4_)6FM
MR87%P83#XO#VP_46MO'$OS"*%K]II4_/74=?@UT]>O8C<00Y?D%QV-N-"2"%
M=K/.6*L;!"`5,6,K<349EE>\MQ[-1H!B-HBMC'S;,$`_9$32!MZ%]-;'?)2?
M\G9+W.U,SXHJ=WBQ=3'"37Q+50U\:FNL$)B(O^?,>/XW06\>85O2>BK'())E
M%/`(%D7;X`+37L)]8XUO?7__U;^//'0?'?D?&V.*[RZSPSXZYN]O;7O'O(;.
MC7[(LF1%M^4C:(>V57'E<L3][CV3=&9E5.Z]H9%T`*,UA4*NBK;_`&EO.9V5
M]>S<<Q)O<75!<1EXXQUKM*/(R@2`5\*U'1A]TBBN]UCP#(8ZP@Y9FQ89>CFU
ME$<LK?H[E=(D<F,G;U-"#4H3ZU,;.#MI\XN).+^/Z3B'%?'/E7AI>L-E,!9F
MOMXM&/)R/QXX1%"JIO*OD-MC'(,I66+0A5XLDI#M7@QQDB$65;>WV[?*H.UF
M1SUY=9&_O,?DA(?Q$*(L@,@^_1H_=C#$]'VN1NK4!MVN%PNX[PXOC5C9XNPL
MLEBC'_LT\C&,B,]$],K6\IC`H4W1@[:;24V@15XD8>XNUWR/2-^\K7+:MW[R
M`/\`*T(E`X&'&V8XO'L!D]TWC#420LV0I[%U;QO+MF$=[`E:9LG*=;2(#4R;
MIX(I$+(.19+/S<)CM.W_`!V2'AXMVW3^Y"9&B%?<"QK*T@J=WN,P]PG<"J]2
M8KQ;$\8M^X<U]W,Y3'/SIKE=ML8IUC64T]LO*T*1-0;/;53[0&TAV6@&SW69
M=:\UGPG:E7S_`"+J7;SY0I"-A1XCOF".*SQF23WMVV&`LR8S24FE0#XR3BRI
MJF4$JEB(]V2$`;]0E`;ABN)AV9N;86$OL_O`'W:Q^V#N7I3W/=KY?Z.G7QU1
M<]K`>_%I='(PB<8ZGLTE]PCVY>M?:]JGGUEKT^[6E9=>32N<1K%9^!AN460Z
MYC^3@.8U#L6*$Y^!LDZ2]S\>R>INL?*#`Q$JPA86P3+F'.]?RQFD6W!NEWER
M"8I31W@T_(H8.6_N*R>:-\;(LNUE7VU)%)/40695#[52KFIH#J3]QK?B]Q<<
M*/(L@EN\>6C>+<KM[I'C$=JL%1W,1=GVH`!N8`]?N_,M"-['XT>4T*]N$!06
M#ZLTXDA;K0UMCV`AF*63J0NY5DVM'K%SM2J#A-(40!G&.C@=0!,!4P.<OR[:
M2F'G&!E6V>9@[T12@8GVI*4+LB=/'JP\/C0:^W=R%;CMYR2%KM($*15=PY51
M[\1-1&DC]?#THW4]:"I%;_QHZ;7Z9@CDVSKN6,?9::/,R5ARM*X^C<J1C2*<
M%HC-(8^11RIC7&LB=T=,I52&:(.4.@VQE"G`2ZF_?&YFN<OA&FQ\UNPMF%)#
M$21O\1[4LHI]I!^6J\^G2TM[/`9U+;*072&Y0EHA,`#M/0^]#"?X`1\]7B<Q
M$^-RO&7,:7+M>OMN.:M/>)Y1<V0'YF+>$.L@5LNS+#HN)TU@2E1;FBPCDSR0
MR((>U*9QVP&JN-'-C.XT\<#G->X/:"TJ6\Z[J+MI7?N].VN[I75T<L''CQW*
MCE3(,`8OUQ:M`*BA&VK;]U-FP%]^W9ZJ:R5>/>B<B<&YUS3:?"WF['O-O`#@
M88V2,:9?JN6L,*1Z#Q:7&ELI^:R-2L>U)Y>X9H*Y49&%E2N738#&=1Q$1(0-
M#\RN\/E<3C+?N=BIL7F!N]N6%XIJT`WE1$\KA&-*JZ4!IM<GKK+?`;'-X;-9
M>Y[0YJ',8$[?=AFCFAI4ML#&9((RZC=M:.2K>HF,+TU?S@V4\O>4LZ8SLO)2
MJ\>N+W'RHOIEY<,;8SG9'+.1,L/WM=EH^!AY6S)(RL-5:W$2ZZ4@HN@NR,<[
M<B2@J@H!2U!E(^W5AB;^#"SWE_F)`H220"*.(!@68*=K,Q`*T(;QJ*4U>N(D
M[HY+-8VXSL%ECL%$S&2*(^[+,2C!59@9%5`Q#U#)X4.ZHIWORD1;6:\>7+V)
M?6.#J#*0PI:FKNSV5"Q.8&#;*IH@O(RC>HP-HLJS5NGN(E91[Q<1VZ4S:Y/`
MI&BYCQV1(7D87*D*NT,QZ]`795K_`$F`^>NUW(C2;@G*(I+A(HVM&!=MQ51T
MJ3L5WZ?S58_+5.GQF*37:7COEPC6\P8ZRZT?WK%2J[O'L5EF+1A'"%;MA/;2
MA<K8QQH[65>)'*=(6:3M("D-W#D-TE-97?.ZFNKWCIFQL]LPBEH)#"=PW)X>
MU+*.GGN(/7H#JH_IQLX+/&\E6WRUO=(TL/6(3C::2^/O0PGKY;0W@:D=*\E^
M2YCOCM=KAQL>6'/6/\/YYBZQ:6SF'OE<S#+Q]FPV_DE%6$E^88KQ;DGV#N!N
MC%TDV1=E;^X3?.3%$>R.NCV.O<S:VV;6'$37.(9U.Z-H05F`ZBDLL50R%22*
MTVK\=<KZB\?@;VZXZ\V<@M,ZJ,-LBSL'A+$HU88)B"L@<*#2N]C^CJ_'QIL<
MYQ/"7`,+R#EZ]9;S#4:(CXJWUU6U]NWX\39-U<<6"98WFLU&VQ-F<4]9HE(M
MI!@@Z!TB<ZI2G.8I:BYP^*DY3F)</&Z6K2DE&V>B2I]Q5,;.A7?4J58BAH.@
MU>7;I,U%PW!19V6.2\6!0KI[GKBH#$S"5$D#^V5#!U#5%2`20*"?.QB?Q]Y&
MS^QD&'*9EQ\\A5?BJ0<]?;XZSE=X?(:*W8-C5G8I/$..KJXJ&16J:;<(AXU%
M5^+8S8B[0Z8M%DK=[3Y#F%EAW1\`;SAKL_J,D"&/_P`0J)I$#QDUW@T6NXAJ
M[@:,[V8O@>0SL<B\F%ASR-4](BN9%EZ#V@S012%)0-NUA5MNT,M-C"5B%P^1
M4?"08H/A[C*E<!K?Y0'*1:]MOWM(Q[(&_>4V.4C*F-=O8?;_`-/@/N/N&/[W
MVZCQMNS/[U_>'[QOOPV^OX78=E?Y/N4^Y7^T\/TZ:E@NN_!PO[L_=MC^,]O;
M^,W+OI3[_M[Z^Y3^QK7^KW:C=X-\5>.+&N<WBO\`BAC^1GD1GF-S<N6TOCK-
M5!CZ$=('G]9$115<NT*G+6B[K$4=#,/W(DEE&I'`)-&Z`.S*]SNKD.:WV*4?
MN%K+AB%`")()#)X>V9/9D?8E:;%'HW;:L3MI&^S&,[?8_-.1R1<ASYPY(:*X
MC$9H?<6,SQ1EY-N[<QH^P-10/<)UC:SWK4.JK?(%8_*5*/1Q9P2QIB:M5*>J
M?O+#RAN]\;O9^FO5%W*,G!UG%3>$E)TT^U8H%6;OD8^>(L5<"HH)N2%U/^(0
M\"C47_*[ZX>X22BVJ1D*XZ49I:A=I/0J6CI2I)4ZK3G-QW(E=L;PS'VT5J\5
M6O))`60]:JL-"P8``A@DM:T50PU7/X.\8>-[&&3K['XPY+K<F.><G7;$]R=8
MK7CK+F-'5=A`L+$EWA*'"97IU8<.URV<41FG:BSJ;<'*!E2-4!.CJ:=U+_FU
M_8VCW^#%CQ)741*DD,H9MIV-(T+L!Z:[``$'D6-#JONS.-[>X[(WR8SD)R/-
AFC8S,\4\15=R[UC6>-"3NIO8DN>IHJ[AK35JC-:,U__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
